Earnings ·
Journey Medical Corporation reported financial results for the second quarter ended June 30, 2026
DERMJourney Medical Corp
Journey Medical Corporation reported financial results for the second quarter ended June 30, 2026. Total revenues increased 23% to $18.5 million from $15.0 million in the prior-year period, driven by Emrosi sales of $8.1 million and total prescriptions reaching approximately 36,000. The company achieved a GAAP net loss of $0.3 million, or $(0.01) per share, compared to a net loss of $3.8 million in the previous year. Selling, general and administrative expenses decreased by $1.0 million to $10.9 million due to reduced launch-related spending. At quarter-end, cash and cash equivalents stood at $25.6 million. Journey Medical Corporation is a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription products for dermatological conditions.